Aeglea biotherapeutics, inc. (AGLE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-18,728

-21,495

-21,573

-18,019

-17,167

-14,898

-11,917

-9,414

-8,119

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-6,632

-6,247

-

-6,238

-5,430

-4,547

-3,987

-3,413

-1,427

-2,468

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

154

106

105

107

100

72

76

75

70

66

69

62

52

36

34

33

29

29

25

18

17

Purchase net discount on marketable securities

-19

-6

-18

-237

-243

-

-

-

-

-7

-42

95

-55

-

-

-

-

-

-

-

-

Net accretion of discount on marketable securities

48

69

206

268

275

282

204

93

14

-

-

-

-

-

-

-

-

-

-

-

-

Net (accretion of discount) amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-2

-129

49

-

-

-

-

-

-

-

-

Purchase premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

16

-

-

-

-

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37

6

8

-

-

-

-

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2

Amortization of lease allowance liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

-

5

6

6

Stock-based compensation

1,348

1,184

1,366

1,245

1,081

1,377

1,072

996

835

698

728

665

401

258

434

389

140

419

164

146

38

Research and development services settled with stock

-

-

-

-

-

0

66

11

30

-

-

-

-

30

30

30

20

117

155

334

206

Non-cash operating lease expense

152

146

146

122

69

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other, net

-

-

-

-

-

10

10

9

11

6

2

8

5

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable - grant

-

-

-

-

-

-2,422

-1,859

908

295

626

1,239

232

-234

-356

-54

7

-79

-

-

-

-

Prepaid expenses and other assets

2,696

-1,354

-523

1,295

928

-1,259

947

471

102

389

-246

122

-151

-337

574

256

431

58

298

50

180

Accounts payable

262

749

-307

-148

2,289

-488

148

183

396

-283

107

245

95

-355

175

-89

261

-386

-227

462

-18

Deferred revenue

-

-

-

-

-

0

0

0

-20

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-92

-93

13

-64

-114

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-20

-

-

-

-

-

-

-

-

Accrued and other liabilities

-2,065

1,823

2,707

1,700

-1,105

2,980

1,217

185

-217

1,180

559

14

-87

520

135

699

475

501

599

93

-74

Net cash used in operating activities

-21,694

-16,294

-17,208

-16,383

-15,807

-7,200

-8,502

-9,044

-7,447

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-5,942

-5,432

-

-5,865

-4,632

-3,988

-833

-3,811

-3,855

-2,483

Purchases of property and equipment

1,389

1,174

143

57

118

203

101

35

83

191

111

46

271

121

0

89

2

40

134

24

10

Purchases of marketable securities

4,000

4,250

9,720

58,206

19,750

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

20,142

15,750

25,875

16,250

33,804

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

24,335

5,000

32,780

0

17,450

0

2,940

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

-

4,785

-

18,160

9,570

7,440

2,680

2,000

2,016

1,750

-

-

-

-

Net cash provided by investing activities

14,753

10,326

16,012

-42,013

13,936

-2,132

1,399

-19,200

4,702

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and pre-funded warrants in public offering, net of offering costs

-

59

-59

-364

64,662

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

10

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

4,524

-25,611

-

-15,295

1,852

-1,192

-510

-3,460

-24

-20

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

98

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-5

6

43,678

Proceeds from employee stock plan purchases and stock option exercises

289

624

376

51

399

867

1,092

373

688

684

53

0

96

-

-

-

-

-

-

-

-

Principal payments on finance lease obligation

7

7

6

6

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

282

676

311

-319

65,055

17,261

1,056

38,063

688

-

-

-

-

-

-

-

-

-

-

-

-

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

-6,659

-5,292

-885

-58,715

63,184

7,929

-6,047

9,819

-2,057

-

-

-

-

-

-

-

-

-

-

-

-

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

11,551

96

-

76

49,392

-98

-203

-970

-831

43,678

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

-

-

-

10,133

-30,947

-

-21,084

46,612

-5,278

-1,546

-8,241

-4,710

41,175

Supplemental Disclosure of Non-Cash Investing and Financing Information:
Leased assets obtained in exchange for lease obligations

137

0

0

4,518

776

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid amounts related to purchase of property and equipment

1,057

-

-

-

-

-

-

-

-

-

-

-

4

-

-

-

-

-

-

6

64

Deemed dividend to Series A convertible preferred stockholders upon conversion from an LLC to corporation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

228